Who has been buying Dongguk Life Science stock?

2 distinct insiders have filed 2 disclosed insider purchases in Dongguk Life Science (303810), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Dongguk Life Science have?

Dongguk Life Science has 2 buy-side and 7 sell-side disclosures on record, covering ₩13.3B ($9.2M) in total reported value, spanning 2025-02-17 to 2026-06-30.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Dongguk Life Science 303810

Company

동국생명과학Dongguk Life Science

Insiders

Buys

Total Value

₩13.3B ($9.2M)

Avg Return

+34.37%

Last Filing

2026-06-30

Dongguk Life Science (303810) has 2 disclosed insider purchases and 7 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩13.3B ($9.2M) in reported transaction value. The earliest filing StockDrifts holds for Dongguk Life Science is dated 2025-02-17; the most recent is 2026-06-30. Across these filings the average return since disclosure is +34.37%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-30	BUY	Market Buy	김영선 Kim Young-seon	Managing Director	10.0K	-	-	-
2026-04-08	BUY	Market Buy	김영선 Kim Young-seon	Managing Director	10.0K	₩3,310	+5.6%	₩33M ($23K)
2025-08-08	BUY	무상신주취득	동국제약 Dongkuk Pharmaceutical	-	6.3M	₩4,570	-18.9%	₩28.9B ($20.0M)
2025-08-08	BUY	PROGRAM	박상훈 Park Sang-hoon	moving	3.8K	₩4,570	-18.9%	₩17M ($12K)
2025-08-08	BUY	PROGRAM	김기철 Kim Ki-cheol	moving	2.1K	₩4,570	-18.9%	₩10M ($7K)
2025-08-08	BUY	PROGRAM	김영선 Kim Young-seon	Managing Director	2.5K	₩4,570	-18.9%	₩11M ($8K)
2025-08-08	BUY	PROGRAM	양희성 Yang Hee-seong	Managing Director	7.6K	₩4,570	-18.9%	₩35M ($24K)
2025-08-08	BUY	무상신주취득	권기범 Kibeom Kwon	Internal director	1.8M	₩4,570	-18.9%	₩8.1B ($5.6M)
2025-08-08	BUY	PROGRAM	박재원 Jaewon Park	CEO	15.0K	₩4,570	-18.9%	₩69M ($48K)
2025-08-08	BUY	PROGRAM	최순호 Soonho Choi	moving	3.4K	₩4,570	-18.9%	₩16M ($11K)
2025-07-29	SELL	Market Sell	라이프밸류업사모투자 Life Value Business Private Investment	-	-852.7K	₩5,085	+27.1%	₩4.3B ($3.0M)
2025-07-28	SELL	Market Sell	라이프밸류업사모투자 Life Value Business Private Investment	-	-360.5K	₩5,015	+26.1%	₩1.8B ($1.3M)
2025-04-01	BUY	신규선임	김기철 Kim Ki-cheol	moving	2.1K	₩4,855	-23.7%	₩10M ($7K)
2025-02-26	SELL	Market Sell	라이프밸류업사모투자 Life Value Business Private Investment	-	-9.8K	₩5,800	+36.1%	₩57M ($39K)
2025-02-25	SELL	Market Sell	라이프밸류업사모투자 Life Value Business Private Investment	-	-93.3K	₩6,080	+39.1%	₩567M ($394K)
2025-02-24	SELL	Market Sell	라이프밸류업사모투자 Life Value Business Private Investment	-	-30.0K	₩6,535	+43.3%	₩196M ($136K)
2025-02-20	SELL	Market Sell	라이프밸류업사모투자 Life Value Business Private Investment	-	-100.0K	₩7,010	+47.1%	₩701M ($487K)
2025-02-19	SELL	Market Sell	라이프밸류업사모투자 Life Value Business Private Investment	-	-750.0K	₩7,480	+50.5%	₩5.6B ($3.9M)
2025-02-17	BUY	신규상장	라이프밸류업사모투자 Life Value Business Private Investment	-	3.1M	₩6,265	-40.9%	₩19.7B ($13.7M)
2025-02-17	BUY	신규상장	박재원 Jaewon Park	CEO	15.0K	₩6,265	-40.9%	₩94M ($65K)
2025-02-17	BUY	신규상장	동국제약 Dongkuk Pharmaceutical	-	6.3M	₩6,265	-40.9%	₩39.6B ($27.5M)
2025-02-17	BUY	신규상장	김영선 Kim Young-seon	Managing Director	2.5K	₩6,265	-40.9%	₩15M ($11K)

Frequently asked questions

Who has been buying Dongguk Life Science stock?: 2 distinct insiders have filed 2 disclosed insider purchases in Dongguk Life Science (303810), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Dongguk Life Science have?: Dongguk Life Science has 2 buy-side and 7 sell-side disclosures on record, covering ₩13.3B ($9.2M) in total reported value, spanning 2025-02-17 to 2026-06-30.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.